vaccinesScienceTrump’s Surgeon General Pick Is Tearing the MAHA Movement ApartBy David GilbertScienceThe Dangerous Decline in Vaccination RatesBy Lauren Goode, Michael Calore, and Katie DrummondScienceAs Measles Cases Surge, Mexico Issues a US Travel AlertBy Javier CarbajalScienceScientists Find Measles Likely To Become Endemic in the US Over Next 20 YearsBy Emily MullinPoliticsAnti-Vaxxers Are Grifting Off the Measles Outbreak—and Claim a Bioweapon Caused ItBy David GilbertScienceMeasles Cases Are Rising. Other Preventable Diseases Could FollowBy Emily MullinScienceCovid Vaccines Have Paved the Way for Cancer VaccinesBy João MedeirosScienceTexas Official Warns Against ‘Measles Parties’ Amid Growing OutbreakBy Beth Mole, Ars TechnicaScienceNearly 100 Measles Cases Have Been Reported in TexasBy Javier CarbajalScienceRFK Jr.’s Senate Testimony Is Haunted by His Track RecordBy Emily MullinPoliticsDonald Trump to Nominate Anti-Vaccine Activist Robert F. Kennedy Jr. to Oversee US Public HealthBy Vittoria ElliottScienceRFK Jr. Wants to Reshape US Health Policy. Good Luck With ThatBy Emily Mullin and Matt ReynoldsScienceThe US Is Loading Up on Bird Flu VaccineBy Emily MullinScienceMaking an RSV Vaccine Was Hard. Getting People to Take It Is Even HarderBy Annika HomScienceBird Flu Fears Stoke the Race for an mRNA Flu VaccineBy Chris BaraniukScienceRSV Can Be a Killer. New Tools Are Identifying the Most At-Risk KidsBy David CoxScienceWhy Polio Has Reemerged in GazaBy Lee SherrySciencePromising Mpox Drug Fails in Trials as Virus SpreadsBy Emily MullinScienceFDA Approves New Covid Vaccines Amid Summer SurgeBy Emily MullinScienceThe Covid-19 Summer Wave Is So Big, the FDA Might Release New Vaccines EarlyBy Beth Mole, Ars TechnicaScienceThis Mpox Outbreak Isn't Like the Last OneBy David CoxScienceUS Government Awards Moderna $176 Million for mRNA Bird Flu VaccineBy Beth Mole, Ars TechnicaScienceThere’s New Hope for an HIV VaccineBy Emily MullinScienceThere Are Already More Measles Cases in the US This Year Than All of 2023By Beth Mole, Ars TechnicaMore Stories
